[DYAX] Dyax Corp.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization: 5.65 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 38.41 Change: 0 (0%)
Ext. hours: 38.04 Change: 0 (0%)

chart DYAX

Refresh chart

Description: Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas. The company offers KALBITOR for the treatment of acute attacks of HAE. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which would be a candidate to prophylactically treat HAE and other PKM disorders. The company distributes KALBITOR through a network of wholesale and specialty pharmacy arrangements. It has agreements with CVie Therapeutics for the development and commercialization of KALBITOR in the treatment of HAE and other angioedema indications in China; and Novellus Biopharma AG for the development and commercialization of KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. The company also has a strategic collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize su

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding147.18 M EPS-0.21 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 4.25% Sales Growth - Q/Q-21.55% P/E-182.91
P/E To EPS Growth P/S64.22 P/BV55.51 Price/Cash Per Share31.08
Price/Free Cash Flow-616.89 ROA-6.36% ROE-13.2% ROI
Current Ratio9.97 Quick Ratio9.75 Long Term Debt/Equity0.45 Debt Ratio0.2
Gross Margin89.1% Operating Margin-3.25% Net Profit Margin-15.27% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities218.86 M Cash From Investing Activities-103.12 M Cash From Operating Activities-7.89 M Gross Profit22.76 M
Net Profit-8.41 M Operating Profit-5.91 M Total Assets427.74 M Total Current Assets413.27 M
Total Current Liabilities22.06 M Total Debt82.11 M Total Liabilities110.58 M Total Revenue26.37 M
Technical Data
High 52 week38.41 Low 52 week14.25 Last close38.41 Last change0%
RSI80.18 Average true range2.93 Beta0.87 Volume
Simple moving average 20 days1.18% Simple moving average 50 days4.52% Simple moving average 200 days35.58%
Performance Data
Performance Week0.31% Performance Month1.91% Performance Quart39.52% Performance Half55.32%
Performance Year140.21% Performance Year-to-date0% Volatility daily0.27% Volatility weekly0.6%
Volatility monthly1.23% Volatility yearly4.27% Relative Volume0% Average Volume3.54 M
New High New Low

News

2018-08-24 08:33:39 | One less hurdle for Shire and Takeda tie-up after potential blockbuster drug wins FDA approval

2016-02-25 12:11:12 | Peter Kolchinsky Is Betting Big On Achillion Pharmaceuticals, Inc. ACHN, Wave Life Sciences WVE & More Heading Into 2016

2016-01-26 13:19:09 | Here Are The Most Notable Insider Transactions Hitting The Market

2016-01-22 16:50:27 | DYAX CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to S

2016-01-22 09:16:00 | Shire Completes Acquisition of Dyax

2016-01-22 09:03:06 | Shire Completes Acquisition of Dyax

2016-01-21 08:00:00 | Technical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and Baxalta

2016-01-20 13:43:23 | 3 Stocks Making New 52-Week Highs

2015-12-29 09:30:02 | The Zacks Analyst Blog Highlights: ALPS Medical Breakthroughs ETF, Anacor Pharmaceuticals, Dyax, Ultragenyx Pharmaceutical and ImmunoGen

2015-12-28 11:33:04 | 5 Top Performing Stocks of the Top ETF of 2015

2015-12-11 16:37:28 | DYAX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2015-12-11 08:09:23 | Dyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed Acquisition By Shire plc

2015-12-11 08:00:00 | Dyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed Acquisition By Shire plc

2015-12-08 13:17:13 | DYAX CORP Financials

2015-12-08 07:15:08 | Dyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology Annual Meeting

2015-12-08 07:15:08 | Dyax Corp. Recognized as a _Top Place to Work_ by The Boston Globe for Second Year in a Row

2015-12-08 07:15:08 | Dyax Corp. Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology Annual Meeting

2015-12-08 07:15:08 | Dyax Corp. Announces Early Termination of Hart-Scott-Rodino Waiting Period

2015-12-07 14:24:00 | Why Dyax Corp Rocketed 22% Higher in November

2015-12-06 09:00:00 | Dyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology Annual Meeting

2015-12-04 11:28:50 | The SPDR S&P Biotech ETF Lingers in the Red as of December 3

2015-12-04 08:00:01 | Strength Seen in Dyax Corp DYAX: Stock Rises 12.2%

2015-12-03 11:05:57 | Here's Why Dyax Corp.'s Shares Jumped Today

2015-12-02 17:32:49 | DYAX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2015-12-02 17:26:00 | Dyax Corp. Announces Early Termination of Hart-Scott-Rodino Waiting Period

2015-12-01 10:45:27 | Do Hedge Funds Love Dyax Corp. DYAX?

2015-11-24 19:01:37 | Is Vista Outdoor Inc VSTO A Good Stock To Buy?

2015-11-07 09:25:51 | 5 BioPharma Movers That Cannot Be Ignored

2015-11-06 16:05:03 | DYAX CORP Files SEC form 10-Q, Quarterly Report

2015-11-02 17:28:01 | DYAX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; C

2015-11-02 12:54:32 | Shire to buy Dyax for $5.9 billion, still wants Baxalta

2015-11-02 12:20:49 | Dyax Agrees to $5.9 Billion Buyout

2015-11-02 11:19:36 | Three Takeover Deals That Have Investors Excited Today

2015-11-02 07:01:07 | Dublin-based Shire to acquire Dyax for initial $5.9 billion

2015-11-02 06:11:10 | Shire to buy Dyax for about $5.9 bln

2015-10-28 17:17:53 | Dyax reports 3Q loss

2015-10-15 15:16:56 | Dyax, Bill Barrett, MeetMe: What You Need To Know About Today’s Hottest Stocks

2015-09-30 14:40:28 | Technician Picks Oversold Biotechs for Large Potential Trading Bounces

2015-09-30 14:05:25 | Dyax Wins Positive Opinion for European Orphan Designation

2015-07-08 15:14:15 | RA Capital’s Latest Move In Alcobra Ltd ADHD Coming Off Hefty Second Quarter Gains

2015-07-07 13:25:41 | What FDA Breakthrough Therapy Designation Means for Dyax

2015-04-07 10:45:56 | Dyax Shares Defy Gravity on Secondary Offering News

2015-04-01 10:15:31 | Analysts Massively Increasing Dyax Price Targets

2015-04-01 08:45:34 | Top Analyst Upgrades and Downgrades: Alibaba, Altera, Dyax, HP, Kinder Morgan, Kors, Staples, Twitter and More

2015-03-31 17:11:43 | Why Dyax Will Dominate Biotech News on Wednesday

2015-03-30 10:15:09 | Merrill Lynch Makes Changes to SMID-Cap Alpha List for Q2